BD Announces $110 Million to Support U.S. Pharmaceutical Supply Chain for Biologic Drugs

BD (NYSE: BDX) announced a $110 million investment to expand production of BD Neopak™ Glass Prefillable Syringes in Columbus, Nebraska, creating about 120 jobs and strengthening U.S. pharmaceutical supply chains.

Rhea-AI Summary

BD (NYSE: BDX) announced a $110 million investment to expand production of BD Neopak™ Glass Prefillable Syringes in Columbus, Nebraska, creating about 120 jobs and strengthening U.S. pharmaceutical supply chains.

The plan allocates $100 million for Neopak syringe production with supply expected in mid-2026 and $10 million to enhance cannula manufacturing; it follows a prior >$35 million Columbus expansion and sits within a broader pledge to invest $2.5 billion in U.S. manufacturing over five years.

Positive

• $110M total investment for U.S. syringe production
• $100M allocated to BD Neopak syringe production in Columbus
• $10M to enhance cannula manufacturing capabilities
• Adds approximately 120 new jobs at Columbus site
• Supply from new line expected by mid-2026
• Part of a $2.5B U.S. manufacturing commitment over five years

Negative

• None.

Argus Jan 13 session

-0.60% close to close Open Argus

Details

News Market Reaction – BDX

In the Jan 13 session, BDX declined 0.60%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights BD’s plan to invest $110 million in Columbus, Nebraska, as part of more...

Analysis

This announcement highlights BD’s plan to invest $110 million in Columbus, Nebraska, as part of more than $2.5 billion earmarked for U.S. manufacturing over the next five years. It adds capacity for Neopak prefillable syringes and cannula production, building on prior investments exceeding $35 million at the site. Investors may track execution timing, uptake in biologics and GLP-1 delivery, and how these projects complement BD’s recent product and collaboration milestones.

Key Figures

Investment amount: $110 million New jobs: approximately 120 jobs Neopak line investment: $100 million +5 more

Investment amount

$110 million

Total announced to expand prefillable syringe production

New jobs

approximately 120 jobs

Jobs expected from Columbus, Nebraska investments

Neopak line investment

$100 million

Establish BD Neopak Glass Prefillable Syringe production at Columbus site

Cannula investment

$10 million

Enhance cannula manufacturing capabilities at Columbus site

Additional jobs

approximately 50 jobs

From >$35 million prefilled flush syringe expansion in Columbus

Prior Columbus investment

more than $35 million

Expansion of prefilled flush syringe manufacturing

U.S. manufacturing plan

more than $2.5 billion

Planned U.S. manufacturing investments over next five years

Site history

more than 75 years

BD Columbus as a strategic manufacturing site

Historical Context

5 past events · Latest: Jan 05

5 events

1. Jan 05

   Clinical trial update

   24h Move

   +2.1%

   PREVENT trial enrollment progress and Phasix prophylactic use milestone.

2. Dec 18

   Research collaboration

   24h Move

   -0.3%

   Immunotherapy-focused flow cytometry collaboration with Penn Institute.

3. Dec 15

   Product expansion

   24h Move

   -1.9%

   New IVDR-certified VIASURE assays for BD MAX System in Europe.

4. Dec 04

   Safety collaboration

   24h Move

   +0.1%

   Collaboration with ChemoGLO to expand hazardous drug contamination testing.

5. Dec 03

   Product launch

   24h Move

   +1.6%

   Launch of new BD FACSDiscover A8 Cell Analyzer configurations.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

glp-1, biologics, autoinjectors, combination products, +4 more

8 terms

glp-1 medical

"helping accelerate biologic and GLP-1 drug delivery and supporting"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

biologics medical

"meet the complex and evolving needs of biologics and combination products"

Biologics are medicines made from living cells or their components rather than from simple chemical recipes, more like a handcrafted product than a mass-produced pill. They matter to investors because they often command higher prices and longer patent protection but also carry greater manufacturing, regulatory and supply risks—so a successful biologic can boost a company’s revenue significantly, while setbacks can quickly affect its stock.

autoinjectors medical

"designed for seamless integration with autoinjectors, enabling flexible, patient-centric"

Autoinjectors are handheld devices that automatically deliver a pre-measured dose of medication through the skin, much like a pre-loaded pen that performs the injection for the user. They matter to investors because they can expand a drug’s commercial reach by making treatment easier, improving patient adherence, enabling home use instead of clinic visits, and creating additional revenue streams from device sales, regulatory approvals, or partnership opportunities.

combination products medical

"needs of biologics and combination products development. Available in 1 mL"

Combination products are medical offerings that merge two or more types of treatments or delivery systems—such as a drug with a medical device or a biological therapy with an implant—into a single product. For investors, they matter because combining parts can raise development cost and regulatory scrutiny but also create stronger competitive advantages, higher pricing power, and stickier customer adoption; think of them like a smartphone that bundles hardware and software into one sold product.

cannula medical

"investing $10 million to enhance cannula manufacturing capabilities at the site"

A cannula is a small, hollow tube that medical staff insert into the body to deliver or remove fluids, medications, or gases—think of it like a medical straw or connector used for IV lines, oxygen therapy, dialysis, or surgical access. Investors track cannulas because regulation, manufacturing capacity, product quality and clinical adoption of these basic but widely used devices can affect sales, reimbursement and the broader performance of companies in medical supplies and devices.

vertically integrated technical

"home to part of the company's vertically integrated cannula manufacturing operations"

Vertically integrated describes a company that owns and controls multiple steps in making and selling its products or services — for example sourcing raw materials, manufacturing, and distribution. Like a bakery that grows its own wheat, mills the flour, bakes the bread and runs the shops, this setup can lower costs, improve quality and speed to market and protect profit margins, but it also requires more capital and can reduce flexibility.

supply chain technical

"commitment to building a more resilient and responsive pharmaceutical supply chain"

A supply chain is the series of steps involved in producing and delivering a product or service, from raw materials to the final customer. It includes all the processes, such as sourcing materials, manufacturing, and distribution, that ensure products reach consumers. For investors, understanding the supply chain helps gauge how efficiently a company can meet demand and manage costs, impacting its profitability and stability.

View in glossary

drug delivery medical

"biopharmaceutical innovators as they bring advanced therapies to patients who require next-generation drug delivery solutions"

Drug delivery is how a medicine is packaged, moved and released inside the body so it reaches the right place at the right time and dose. Think of it like a shipping and packaging system that affects a product’s effectiveness, side effects and convenience; better delivery can make a drug work longer, be safer, or be easier to use. Investors care because delivery methods influence a therapy’s market value, regulatory approval, manufacturing costs and competitive advantage.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Introduces BD Neopak™ Glass Prefillable Syringe production in Columbus, Nebraska

FRANKLIN LAKES, N.J., Jan. 13, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $110 million investment to expand its production of prefillable syringes, helping accelerate biologic and GLP-1 drug delivery and supporting pharmaceutical reshoring in the U.S. This investment will bring BD Neopak™ Glass Prefillable Syringe production to Columbus, Nebraska, creating approximately 120 new jobs and reinforcing the company's supply resilience within its Pharmaceutical Systems portfolio.  

"This is good news for Nebraska," said Sen. Ricketts. "It has the potential to bring over 100 new jobs to our state. This investment further underscores BD's ongoing commitment to keep critical manufacturing in states like Nebraska. I appreciate BD's long-standing partnership with the Cornhusker State."

The BD Neopak™ Glass Prefillable Syringe platform is purpose-built to meet the complex and evolving needs of biologics and combination products development. Available in 1 mL and 2.25 mL formats, the BD Neopak™ Glass Prefillable Syringe supports a wide range of formulation requirements, including high viscosity, drug-container compatibility, and integration with delivery devices. It is designed for seamless integration with autoinjectors, enabling flexible, patient-centric drug delivery in both clinical and at-home settings.

"As demand for biologics and GLP-1s accelerates, BD is strengthening its American manufacturing footprint to support U.S.-based drug delivery innovation and supply chain resiliency," said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. "This investment in Nebraska, advances our long-term growth strategy and reflects our commitment to partnering with biopharmaceutical innovators as they bring advanced therapies to patients who require next-generation drug delivery solutions."

Strategic Investments in Columbus, Nebraska
BD is investing $100 million to establish BD Neopak™ Glass Prefillable Syringe production at its Columbus site, with supply expected to begin in mid-2026. This investment will also support additional line upgrades and capacity improvements across the site, ensuring BD can meet growing global demand for advanced injectable solutions. In addition, BD is investing $10 million to enhance cannula manufacturing capabilities at the site, and together these investments will add approximately 120 new jobs.

This announcement builds on BD's recent investment of more than $35 million to expand prefilled flush syringe manufacturing in Columbus, which will add approximately 50 new jobs and strengthen the supply of critical medical devices to health care providers across the U.S. BD Columbus has been a strategic site within BD's global manufacturing network for more than 75 years and is home to part of the company's vertically integrated cannula manufacturing operations, including design and production. As the largest medical device manufacturer in the United States, these investments are part of BD's commitment to invest more than $2.5 billion in U.S. manufacturing capabilities over the next five years.

Strengthening U.S. Supply Chain Resilience
This expansion underscores the company's commitment to building a more resilient and responsive pharmaceutical supply chain in the United States. By localizing production of the BD Neopak™ Glass Prefillable Syringe platform, BD is helping to ensure continuity, scalability, and speed to market for life-changing injectable therapies – especially as demand rises for biologics and combination products used to treat chronic and high-burden diseases.

As the global leader in biologics drug delivery, BD continues to invest in innovation and infrastructure to meet current needs and ensure that patients everywhere can benefit from the therapies of tomorrow. 

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson

Additional Quotes for Media Use
U.S. Senator Deb Fischer:
"It's encouraging to see companies like BD continue to invest and expand in Nebraska, which will strengthen our economy and provide good-paying jobs for hundreds of hard-working Nebraskans."

U.S. Congressman Mike Flood:
"Once again, BD is stepping up and creating more great opportunities in Columbus, Nebraska. Americans want to see more manufacturers choose to make things right here at home, and BD is doing just that. Congratulations to BD and the City of Columbus on this announcement, and I look forward to seeing BD continue to grow in the years to come."

Nebraska Governor Jim Pillen:
"This is another perfect example of a company with global reach producing high value, cutting edge products at its plant right here in Nebraska. We can compete with anyone in the world and we are the best at what we do because of our people. The announcement of this expansion for BD is exciting news." 

Contacts:
Media	Investors
Fallon McLoughlin Director, Public Relations 201.258.0361  Fallon.Mcloughlin@bd.com	Adam Reiffe  Vice President, Investor Relations 201.847.6927         Adam.Reiffe@bd.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-announces-110-million-to-support-us-pharmaceutical-supply-chain-for-biologic-drugs-302658610.html

SOURCE BD (Becton, Dickinson and Company)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BD (BDX) announce on January 13, 2026 about U.S. manufacturing?

BD announced a $110 million investment to add BD Neopak syringe production and cannula upgrades in Columbus, Nebraska.

How many jobs will BD's Columbus, Nebraska expansion create for BDX?

The investment is expected to create approximately 120 new jobs at the Columbus site.

When will BD (BDX) begin supply from the new Neopak syringe production line?

BD expects supply from the Columbus Neopak production line to begin in mid-2026.

How much of the $110 million is dedicated to Neopak syringe production for BDX?

$100 million is allocated to establish BD Neopak Glass Prefillable Syringe production at Columbus.

What broader U.S. manufacturing commitment did BD (BDX) reference in the announcement?

BD said these investments are part of a plan to invest more than $2.5 billion in U.S. manufacturing capabilities over five years.